Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...
UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...
EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...
Alaunos Therapeutics (NASDAQ:TCRT) is developing a library of T-cell receptor (TCR) cell therapies with the potential to revolutionize the treatment of solid tumors.
Rezolute (NASDAQ:RZLT) is working on therapies targeting both ends of the spectrum of dysregulated glucose. It has now entered Phase 2 with an oral therapy to treat diabetic macular edema (DME), a big market...
Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.
Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.
Enveric Biosciences (NASDAQ:ENVB) has created a library of more than 500 new chemical entities from its drug platform, including next generation psilocybin analogues for the treatment of anxiety, depression, and...
bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.
Privately-held Conavi Medical’s Novasight Hybrid System represents a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.